Targeted drugs for metastatic renal cell carcinoma Journal Article

  

Authors:	Motzer, R. J.; Basch, E.
Article Title:	Targeted drugs for metastatic renal cell carcinoma
Keywords:	cancer survival; treatment response; survival analysis; vascular endothelial growth factor a; clinical trial; disease course; drug tolerability; sorafenib; angiogenesis inhibitor; bevacizumab; interferon; placebo; sunitinib; monotherapy; drug targeting; quality of life; controlled clinical trial; multiple cycle treatment; randomized controlled trial; combination chemotherapy; antineoplastic activity; kidney carcinoma; kidney neoplasms; temsirolimus; cost effectiveness analysis; drug cost; antibodies, monoclonal; carcinoma; alpha2a interferon; indoles; pyrroles; double-blind method; angiogenesis inhibitors; kidney metastasis; sirolimus; costs and cost analysis; interferon alfa-2a
Journal Title:	Lancet
Volume:	370
Issue:	9605
ISSN:	0140-6736
Publisher:	Elsevier Science, Inc.
Date Published:	2007-12-22
Start Page:	2071
End Page:	2073
Language:	English
DOI:	10.1016/s0140-6736(07)61874-1
PUBMED:	18156012
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-37349092104&partnerID=40&md5=1f48c66b8f7a862be221fa627d1f335f
Notes:	--- - "Cited By (since 1996): 24" - "Export Date: 17 November 2011" - "CODEN: LANCA" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/17901